The SENSOPAD project represents a groundbreaking leap in the realm of women’s health, particularly in addressing the challenges posed by ED. For over four decades, innovation in ED early diagnosis and disease monitoring has stagnated, leaving a significant gap in proactive healthcare.
The visionary approach of SENSOPAD involves empowering individuals through SENSOPADs, sophisticated sensors designed for self-monitoring. These devices employ cutting-edge technology to efficiently detect relevant biomarkers, providing users with valuable insights during their menstrual cycles. If initial readings indicate potential concerns, a seamless transition occurs, guiding users to employ the SENSOPAD Microfluidic graphene Field Effect Transistor sensoMFgFET device at clinical entry points.
This transition from self-monitoring to clinical assessment establishes a holistic approach, merging the convenience of at-home monitoring with the precision of clinical tools. The ultimate goal is to reduce the average time to ED diagnosis from an alarming eight years to just a few days, revolutionizing the healthcare landscape.
BIOG3D is involved in the fabrication of SENSOPAD prototypes through advanced 3D printing technologies that integrate sensors, while also perform in-vitro assessment for the evaluation of developed materials and devices.
